Tennessee is currently home to 1930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
NCT05429502
Recruiting
This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
02/27/2025
Locations: St Jude s Childrens Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
NCT04769206
Recruiting
Specific Aim 1: To test the hypothesis that prolonged (3-month) treatment with galantamine inhibits NADPH IsoLG-protein adducts formation and improves markers of endothelial cell (EC) dysfunction in AAs. Aim 1a: The investigators will determine if galantamine inhibits NADPH IsoLG-protein adducts formation, superoxide production, and immune cell activation compared to placebo. For this purpose, the investigators will study peripheral blood mononuclear cell (PBMC), a critical source of systemic... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/27/2025
Locations: Chaney Johnson, Nashville, Tennessee
Conditions: Endothelial Dysfunction
Register for Updates
Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children
NCT04371315
Recruiting
Patient are being asked to provide respiratory and blood samples for a clinical research study because the patients have a virus called the novel coronavirus, or SARS-CoV-2, that causes the disease known as Covid-19. Investigators do not know a lot about this virus, including all the ways it travels from person to person. Investigators also do not know if a person will get sick or not from the virus after being in close contact with someone who has the virus. Because of this, investigators are... Read More
Gender:
ALL
Ages:
24 years and below
Trial Updated:
02/27/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Corona Virus Infection, Pediatric Cancer, Adult Children, Cancer
Register for Updates
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Recruiting
This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
02/27/2025
Locations: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
Conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer
NCT06849518
Recruiting
This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Ballad Health Cancer Care, Kingsport, Tennessee
Conditions: Lung Cancer (NSCLC)
Register for Updates
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245
Recruiting
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Tennessee Oncology - Chattanooga - Medical Park II, Chattanooga, Tennessee
Conditions: Patients With Non-Small Cell Lung Cancer
Register for Updates
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/26/2025
Locations: Research Site, Memphis, Tennessee
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251
Recruiting
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Local Institution - 0008, Nashville, Tennessee
Conditions: Relapsed and/or Refractory Multiple Myeloma
Register for Updates
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Advanced Solid Malignancies
Register for Updates
Exactech Shoulder Post Market Clinical Follow-up Study
NCT05603728
Recruiting
The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/26/2025
Locations: Bone and Joint Institute of Tenessee, Franklin, Tennessee
Conditions: Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Register for Updates
A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT05234567
Recruiting
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Clinical Trial Site, Nashville, Tennessee
Conditions: Hypophosphatasia
Register for Updates
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: CHI Memorial Hospital, CommonSpirit, Chattanooga, Tennessee
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Register for Updates